Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
1. A method of preparing a separated, amplified target loci DNA sample for analysis comprising the steps of:
(a) providing a reaction mixture comprising bisulfite modified DNA from histologically normal prostate tissue of a subject, and (i) a pair of primers designed to amplify specifically target loci DNA consisting essentially of SEQ ID NO: 102, wherein the primer pair comprises a first and a second primer, (ii) a polymerase, and (iii) a plurality of free nucleotides comprising adenine, thymine, cytosine and guanine;
(b) heating the reaction mixture to a first predetermined temperature for a first predetermined time;
(c) cooling the reaction mixture to a second predetermined temperature for a second predetermined time under conditions to allow the first and second primers to hybridize with their complementary sequences on the bisulfite modified DNA;
(d) repeating steps (b) and (c) at least 10 times wherein an amplified DNA sample comprising amplified target loci DNA of SEQ ID NO: 102 is formed; and
(e) separating the amplified target loci DNA of SEQ ID NO: 102 from the amplified DNA sample, wherein a separated, amplified target loci DNA sample is formed, wherein the primer pair consists of SEQ ID NO: 98 and SEQ ID NO: 99 or the amplicon consists of SEQ ID NO: 102.
2. The method of claim 1 wherein (iv) PCR reaction buffer and (v) MgCl 2 are additionally added to step (a).
3. The method of claim 1 wherein the primers are specific for methylated sequences.
4. The method of claim 1 wherein the histologically normal prostate tissue is obtained from a biopsy sample from the subject.
5. The method of claim 1 , wherein the primers are designed to amplify a sequence consisting of SEQ ID NO:102.
6. The method of claim 1 , wherein at least one primer is biotinylated.
7. A method of preparing a separated, amplified target loci DNA sample for analysis comprising the steps of:
(a) providing a reaction mixture comprising bisulfite modified DNA from a urine or semen sample from a subject, and (i) a pair of primers designed to amplify target loci DNA consisting essentially of SEQ ID NO: 102, wherein the primer pair comprises a first and a second primer, (ii) a polymerase and (iii) a plurality of free nucleotides comprising adenine, thymine, cytosine and guanine;
(b) heating the reaction mixture to a first predetermined temperature for a first predetermined time;
(c) cooling the reaction mixture to a second predetermined temperature for a second predetermined time under conditions to allow the first and second primers to hybridize with their complementary sequences on the bisulfite modified DNA;
(d) repeating steps (b) and (c) at least 10 times wherein an amplified DNA sample comprising amplified target loci DNA of SEQ ID NO: 102 is formed; and
(e) separating the amplified target loci DNA of SEQ ID NO: 102 from the amplified DNA sample, wherein a separated, amplified target loci DNA sample is formed, wherein the primer pair consists of SEQ ID NO: 98 and SEQ ID NO: 99 or the amplicon consists of SEQ ID NO: 102.
8. The method of claim 7 , wherein (iv) PCR reaction buffer and (v) MgCl 2 are additionally added to step (a).
9. The method of claim 7 , wherein the primers are designed to amplify a sequence consisting of SEQ ID NO:102.
10. The method of claim 7 , wherein at least one primer is biotinylated.
11. The method of claim 1 , additionally comprising quantifying methylation in the separated, amplified target loci DNA sample.
12. The method of claim 11 , wherein methylation is quantified using pyrosequencing.
13. A method for identifying a prostate cancer field defect in a subject comprising
quantifying methylation in SEQ ID NO:101 quantifying methylation in SEQ ID NO: 101 by preparing a separated, amplified target loci using to the method set forth in claim 1 and then quantifying the methylation using the amplicon, wherein an increase in methylation in the bisulfite-modified DNA from the subject relative to methylation in a corresponding bisulfate-modified DNA sample taken from a human subject known not have prostate cancer indicates presence of a prostate cancer field defect in the subject.
14. The method of claim 13 , wherein methylation is quantified using pyrosequencing.
15. A method for identifying a prostate cancer field defect in a subject comprising
quantifying methylation in SEQ ID NO:101 quantifying methylation in SEQ ID NO: 101 by preparing a separated, amplified target loci using to the method set forth in claim 1 and then quantifying the methylation using the amplicon, wherein an increase in methylation in the bisulfite-modified DNA from the subject relative to methylation in a corresponding bisulfite-modified DNA sample from a human subject known not have prostate cancer indicates presence of a prostate cancer field defect in the subject.